SLC5A2 and heart failure: The EMPA-REG OUTCOME trial reported that empagliflozin, a SGLT2 inhibitor,significantly reduced the risk of cardiovascular mortality, all-cause mortality,and heart failure hospitalization in high cardiovascular risk patients with T2Dcompared to placebo [36].